Mirum Shares Gain as FDA Approval Validates Rare-Disease Drug Strategy
Mirum shares rose 1.0% to $90.23 as FDA approval transformed a key regulatory question into a confirmed catalyst for Nasdaq-listed MIRM.
Eli Lilly Expands Olumiant Reach With FDA Approval for Adolescent Alopecia
FDA approval for adolescent alopecia broadens Olumiant’s reach and reinforces Eli Lilly’s immunology strategy beyond GLP-1 drugs.
Trade with the conviction of the 1%.
Institutional-grade market intelligence delivered before the opening bell.
Merck Wins FDA Approval for Welireg-Lenvima Combination in Advanced Kidney Cancer
Merck’s Welireg-Lenvima approval expands its oncology portfolio and may influence long-term revenue models as patent-cli…
Grail Stock Jumps 55% After FDA Panel Supports Multi-Cancer Detection Test
Grail shares surged 55% through Friday morning after a favorable FDA advisory vote on its multi-cancer early detection t…
Iovance Shares Rally as Survey Points to Strong Amtagvi Demand in Melanoma
A proprietary analyst survey is lifting sentiment around IOVA, but its demand signal is not the same as confirmed sales …
Abeona Shares Draw Buy Rating After FDA Approval of FAYUVI Gene Therapy
H.C. Wainwright reiterated a Buy rating on Abeona after FDA approval of partner Ultragenyx’s FAYUVI gene therapy for ped…
Eli Lilly Shares Rise 3.7% After FDA Clears Once-Weekly Onswik Insulin
FDA approval of once-weekly Onswik lifted LLY shares 3.73%, adding another pillar to Eli Lilly’s diabetes and metabolic-…
GoDaddy Stock Jumps 6% as Reported Gen Digital Takeover Interest Sparks Fresh M&A Focus
GoDaddy shares jumped about 6% after a report of takeover interest from Gen Digital, putting deal confirmation and terms…
MGM Resorts Stock Drops 9% After People Inc. Withdraws Takeover Offer
MGM Resorts shares fell 9% after People Inc. withdrew its offer, removing takeover-premium expectations and raising caut…
Eli Lilly Stock Nears $1,200 After Weekly Insulin Approval and $3.25 Billion InnoCare Deal
Eli Lilly shares reached $1,191.92 after FDA approval of weekly insulin Onswik and a $3.25 billion InnoCare agreement br…
Elmet Group's Strategic Move: Acquiring Stake in Tungsten Supply Amid Rising Demand
Elmet Group's $125 million acquisition signals a pivotal shift in the tungsten supply landscape for the U.S. market.